title: Use of Survivorship Care Plans and Analysis of Patient-Reported Outcomes in Multinational Patients With Lung Cancer.
abstract: Lung cancer is the leading cause of cancer death and is a significant source of morbidity. Patient-reported outcomes (PROs) have been shown to be prognostic for survival. We have analyzed emerging patterns of longitudinal PROs collected in the development of survivorship care plans (SCPs).
  
  
  
  OncoLife and the LIVESTRONG Care Plans are Internet-based programs designed to generate unique SCPs. We selected SCPs from patients identifying as survivors of primary lung cancer. Patient-reported demographics and treatment and toxicity data were examined. Effects were categorized by the physiologic system that they affected.
  
  
  
  Six hundred eighty-nine plans were created for users self-identifying as survivors of primary lung cancer. Average time from diagnosis to reporting was 1.68 years (range, 0 to 24 years). Most were white (85.9%), well educated (61.1% "some college" or higher), and lived in the United States (90.7%). Patients underwent chemotherapy (75.8%), radiotherapy (54.7%), and surgery (54.4%). Neurocognitive symptoms (eg, fatigue, cognitive changes) were the most common (48.8%), especially among those receiving chemotherapy, followed by musculoskeletal/dermatologic symptoms (14.1%) and thoracic symptoms (13.5%). Only 11.2% were initially offered an SCP. Of those offered SCPs, 54.5% were offered by their health care provider, and most often were at a non-university-based cancer center (66.2%).
  
  
  
  For patients with lung cancer worldwide, it is feasible to obtain PROs and to create SCPs through an Internet-based program. As patients with lung cancer achieve improved survival, further attention should be paid to PROs. Surprisingly, neurocognitive symptoms seem to be the most common issues and therefore the most important to address. Increased effort should be made to provide SCPs, particularly in urban and university cancer center settings.
authors.affiliation: University of Pennsylvania, Philadelphia, PA abigail.berman@uphs.upenn.edu.
authors.forename: Abigail T
authors.initials: AT
authors.lastname: Berman
authors.affiliation: University of Pennsylvania, Philadelphia, PA.
authors.forename: Cristina M
authors.initials: CM
authors.lastname: DeCesaris
authors.affiliation: University of Pennsylvania, Philadelphia, PA.
authors.forename: Charles B
authors.initials: CB
authors.lastname: Simone
authors.affiliation: University of Pennsylvania, Philadelphia, PA.
authors.forename: Carolyn
authors.initials: C
authors.lastname: Vachani
authors.affiliation: University of Pennsylvania, Philadelphia, PA.
authors.forename: Gloria
authors.initials: G
authors.lastname: DiLullo
authors.affiliation: University of Pennsylvania, Philadelphia, PA.
authors.forename: Margaret K
authors.initials: MK
authors.lastname: Hampshire
authors.affiliation: University of Pennsylvania, Philadelphia, PA.
authors.forename: James
authors.initials: J
authors.lastname: Metz
authors.affiliation: University of Pennsylvania, Philadelphia, PA.
authors.forename: Christine
authors.initials: C
authors.lastname: Hill-Kayser
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects; D005260:Female; D006801:Humans; D020407:Internet; D008175:Lung Neoplasms / Q000188:drug therapy / Q000523:psychology / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010347:Patient Care Planning; D000071066:Patient Reported Outcome Measures; D011878:Radiotherapy / Q000009:adverse effects; D017741:Survivors; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents